Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 4/20 | 0.69 |
| ▸ | CES1 | P23141 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127516 | 0.95 | TTR (0.75) | TTRCES1MAPTDRD2HTR6 | |
| SCHEMBL22879308 | 0.84 | TTR (0.55) | TTRCES1MAPTDRD2HTR6 | |
| SCHEMBL13039623 | 0.82 | TTR (0.69) | TTRCES1MAPTDRD2HTR6 | |
| SCHEMBL126628 | 0.82 | CES1 (1.00) | TTRCES1CASP3RAB9ATRPA1 | |
| SCHEMBL30077375 | 0.82 | TTR (0.69) | TTRCES1MAPTDRD2HTR6 | |
| SCHEMBL28252336 | 0.82 | CES1 (1.00) | TTRCES1CASP3RAB9ATRPA1 | |
| SCHEMBL24119646 | 0.81 | TTR (0.52) | TTRCES1MAPTDRD2HTR6 | |
| SCHEMBL21311761 | 0.81 | MAPT (0.67) | TTRCES1MAPTDRD2HTR6 | |
| SCHEMBL17080081 | 0.81 | CES1 (0.58) | TTRCES1MAPTDRD2HTR6 | |
| SCHEMBL12043657 | 0.81 | TTR (0.52) | TTRCES1MAPTDRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019161781-A1 | RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF | 北京泰德制药股份有限公司 | 2019-08-29 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | TTR 4011/4885CES1 2253/4885MAPT 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.